AMSTERDAM – The European Union’s executive commission gave the green light Wednesday to Moderna Inc.’s COVID-19 vaccine, providing the 27-nation bloc with a second vaccine to use in the desperate battle to tame the virus rampaging across the continent.
The European Commission granted conditional marketing authorization for the vaccine. The decision came against a backdrop of high infection rates in many EU countries and strong criticism of the slow pace of vaccinations across the region of some 450 million people.
Recommended Videos
“We are providing more COVID-19 vaccines for Europeans. With the Moderna vaccine, the second one now authorized in the EU, we will have a further 160 million doses. And more vaccines will come," European Commission President Ursula von der Leyen said in a statement.
The EMA recommended the conditional authorization following a meeting earlier Wednesday.
“This vaccine provides us with another tool to overcome the current emergency,” said EMA Executive Director Emer Cooke. “It is a testament to the efforts and commitment of all involved that we have this second positive vaccine recommendation just short of a year since the pandemic was declared by WHO.”
The EMA last month granted the same conditional approval to a coronavirus vaccine made by American drugmaker Pfizer and Germany’s BioNTech. Both vaccines require giving people two shots.
The EU has ordered 80 million doses of the Moderna vaccine with an option for a further 80 million. The bloc also has committed to buying 300 million doses of the Pfizer-BioNTech vaccine.
Commissioner for Health and Food Safety Stella Kyriakides said that the vaccine authorization “will ensure that 460 million doses will be rolled out with increasing speed in the EU, and more will come. Member States have to ensure that the pace of vaccinations follows suit.”
German Health Minister Jens Spahn — who has in the past been critical of the slow pace of the EMA — said shortly before the announcement of the EMA authorization that he expected the Moderna vaccine to begin rolling out to EU nations next week. Germany would get 2 million doses in the first quarter and 50 million in all of 2021, Spahn told reporters in Berlin.
“The problem is the shortage of production capacity with global demand,” he said.
Spahn said that if further vaccines beyond the BioNTech-Pfizer and Moderna shots are approved in the EU, “we’ll be able to offer everyone in Germany a vaccine by the summer.”
He insisted that the strategy of bulk-buying for the entire bloc had been the right one as it had given manufacturers certainty to go ahead with production and ensured fair distribution among all the 27 EU countries.
Early results of large, still unfinished studies show both the Moderna and the Pfizer-BioNTech vaccines appear safe and strongly protective, although Moderna’s is easier to handle since it doesn’t need to be stored at ultra-frozen temperatures.
The EU agency gave the green light to use the Moderna vaccine on people age 18 year and above. It said side effects “were usually mild or moderate and got better within a few days after vaccination.”
The most common side effects are “pain and swelling at the injection site, tiredness, chills, fever, swollen or tender lymph nodes under the arm, headache, muscle and joint pain, nausea and vomiting,” the EMA said.
Cook stressed that EU authorities “will closely monitor data on the safety and effectiveness of the vaccine to ensure ongoing protection of the EU public. Our work will always be guided by the scientific evidence and our commitment to safeguard the health of EU citizens.”
The United States, Canada and Israel have already authorized use of the Moderna vaccine. The U.S. gave it the green light for emergency use in people over 18 years on Dec. 18, followed by Canada five days later with an interim authorization also for people over 18. Israel authorized the vaccine on Monday.
Moderna said Monday that it is increasing its estimate for global vaccine production in 2021 from 500 to 600 million doses. The company said it is “continuing to invest and add staff to build up to potentially 1 billion doses for 2021.”
Both Moderna’s and Pfizer-BioNTech’s shots are mRNA vaccines, made with a groundbreaking new technology. They don’t contain any coronavirus – meaning they cannot cause infection. Instead, they use a piece of genetic code that trains the immune system to recognize the spike protein on the surface of the virus, ready to attack if the real thing comes along.
The EU officially began giving out Pfizer-BioNTech vaccination shots on Dec. 27, but the speed of each nation’s inoculation program has varied widely. France vaccinated around 500 people in the first week, while Germany vaccinated 200,000. The Dutch were only beginning to give out vaccine shots Wednesday, the last EU nation to start doing so.
Austrian Chancellor Sebastian Kurz tweeted that approval of the Moderna vaccine “is another important step in the fight against the pandemic. This means we have more vaccine available in the EU and can fight the pandemic faster.”
___
Mike Corder reported from The Hague, Netherlands. Associated Press writer Frank Jordans in Berlin contributed to this report.
___
Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak